Related Experiment Videos
[Correlation between specific prostatic antigen and findings with total body bone scintigraphy]
M López1, L Montes De Oca, N Bernardo
1Servicio de Urología, Hospital de Clínicas José de San Martin, Buenos Aires, Argentina.
Archivos Espanoles De Urologia
|November 1, 1996
Summary
Prostate-specific antigen (PSA) levels effectively predict bone scan results in prostate cancer patients. Bone scintiscanning may be unnecessary for patients with PSA < 20 ng/ml and no bone pain, reducing costs.
Area of Science:
- Oncology
- Nuclear Medicine
- Urology
Background:
- Prostate cancer diagnosis and staging often involve assessing bone metastasis.
- Bone scintiscanning is a common imaging technique used to detect bone metastases.
- Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
Purpose of the Study:
- To evaluate the correlation between PSA levels, bone symptoms, and bone scintiscan findings.
- To determine the clinical utility of total body bone scintiscanning in prostate adenocarcinoma patients.
Main Methods:
- Retrospective analysis of 129 prostate adenocarcinoma patients.
- Correlation of PSA values, presence of bony symptoms, and bone scintiscan results.
- Categorization of patients based on PSA levels (< 20 ng/ml, 20-50 ng/ml, > 50 ng/ml).
Main Results:
- Bone scintiscans were positive in 3.1% of patients with PSA < 20 ng/ml, 45.8% with PSA 20-50 ng/ml, and 70.8% with PSA > 50 ng/ml.
- All patients with PSA < 20 ng/ml and no bony symptoms had negative bone scans.
- All patients with PSA > 20 ng/ml and bony symptoms had positive bone scans.
Conclusions:
- PSA levels are a reliable predictor of bone scintiscan findings in prostate cancer.
- Total body bone scintiscanning can be omitted in patients with PSA < 20 ng/ml and no bony symptoms.
- Omitting unnecessary bone scintiscans can reduce healthcare costs without compromising patient care.